The FDA has given its blessing to Emergent BioSolutions' intravenous immune globulin drug Anthrasil as a treatment in combination with appropriate antibacterials for inhalational anthrax, which is caused by breathing in the spores of the bacterium Bacillus anthracis.
When inhaled, the anthrax bacteria replicate in the body and produce toxins that can cause massive and irreversible tissue injury...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
